Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898546 | 0.99 | RECQL (0.31) | GAAMAPTSLC2A1 | |
| SCHEMBL9897685 | 0.94 | RECQL (0.32) | CYP2C9TSHRCYP2C19 | |
| SCHEMBL9897537 | 0.93 | EDNRA (0.34) | KDM4EMEN1ALDH1A1LMNACYP2C9 | |
| SCHEMBL9899021 | 0.91 | — | — | |
| SCHEMBL9897534 | 0.88 | MAPT (0.33) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL9897863 | 0.87 | HTT (0.33) | KDM4EALDH1A1HTT | |
| SCHEMBL15954429 | 0.85 | ALDH1A1 (0.32) | KDM4EMEN1ALDH1A1LMNACYP2C9 | |
| SCHEMBL9899290 | 0.83 | TSHR (0.32) | MEN1ALDH1A1LMNACYP2C9TSHR | |
| SCHEMBL9898857 | 0.83 | TSHR (0.31) | CYP2C9TSHRCYP2C19 | |
| SCHEMBL9926885 | 0.83 | GAA (0.35) | GAAMAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120145973-A1 | Photochromic Materials That Include Indeno-Fused Naphthopyrans | TRANSITIONS OPTICAL INC. (US) | 2012-06-14 | — | — | US | claimed |
| US-9028728-B2 | Photochromic materials that include indeno-fused naphthopyrans | TRANSITIONS OPTICAL, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120145973-A1 | Photochromic Materials That Include Indeno-Fused Naphthopyrans | TRANSITIONS OPTICAL INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145973-A1 | Photochromic Materials That Include Indeno-Fused Naphthopyrans | NQO1, INTS6, IPO4 | GAA 2984/4885MAPT 2224/4885SLC2A1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.